Intrinsic Imaging Awarded Important Clinical Trial for the Evaluation of Breast Disease

Intrinsic Imaging Awarded Important Clinical Trial for the Evaluation of Breast Disease

San Antonio (TX), Bolton (MA), (PRWEB) January 10, 2012

Intrinsic Imaging, an ISO 9001:2008 certified medical imaging core lab providing clinical image management and radiological review services in support of pharmaceutical, biotechnology, medical device and clinical research organizations, announces today that it was recently awarded an important clinical trial for the evaluation of breast cancer.

Over the duration of this clinical trial, Intrinsic Imaging will provide its wealth of breast imaging and clinical trial expertise, as well as provide its team of over 60 subspecialized radiologists, to evaluate the product’s clinical safety and effectiveness. This trial, which will be managed from Intrinsic Imaging’s Bolton and San Antonio locations, consists of nearly 3,000 reviews.

“Intrinsic Imaging’s board-certified, breast imaging radiologists currently manage over 150,000 breast related images annually and are responsible for the full complement of imaging and intervention as it relates to the evaluation, diagnosis, prognosis and progression of breast disease. ” said Richard Benedikt, M.D., MBA, Medical Director, Breast Imaging at Intrinsic Imaging. “Our team has extensive expertise in the field of breast cancer and routinely performs all elements of breast cancer imaging including but not limited to full field digital mammography (FFDM) with Computer Assisted Detection (CAD), whole breast ultrasound, MRI, PET/CT, and nuclear medicine Imaging.”

The American Cancer Society estimates that in 2012 about 577,190 Americans are expected to die of cancer, more than 1,500 people a day. Breast cancer, defined as a malignant tumor that starts in the cells of the breast and may eventually invade surrounding tissues or metastasize to distant areas of the body, is the most common cancer among American women. In 2012, approximately 226,870 new cases of breast cancer are expected to be diagnosed among women.

“Today more and more breast cancer trials are underway and are becoming increasingly complex. Intrinsic Imaging is proud to contribute our operational and therapeutic expertise in breast cancer clinical trials and to contribute to the successful evaluation of a new product’s clinical safety and effectiveness.” said Todd A. Joron, BSc. MBA, President and Chief Operating Officer, Intrinsic Imaging.


About Intrinsic Imaging LLC
Located in Bolton, Massachusetts and San Antonio, Texas, Intrinsic Imaging is an FDA audited, ISO 9001, ISO 13485, ISO 22301 and ISO 27001 certified and GAMP5 compliant medical imaging core lab specializing in providing imaging core lab services for clinical trials. With its team of more than seventy board-certified fellowship trained radiologists, robust and scalable clinical imaging technologies and its ISO certified quality management systems, Intrinsic Imaging is ideally positioned to provide unprecedented imaging core lab services around the world.